Docket No.: 026038.0376PTUS (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Brian R. MacDonald et al.

Application No.: 10/667,096 Confirmation No.: 1638

Filed: September 18, 2003 Art Unit: 1647

For: METHODS OF INCREASING PLATELET Examiner: B. E. BUNNER
AND HEMATOPOIETIC STEM CELL.

PRODUCTION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be considered for this application.

This Supplemental Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted concurrently.

In accordance with 37 CFR § 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Similarly, copies of Office Actions issued in related U.S. patent applications directed to similar subject matter, also stored and available to the Examiner in electronic form in the Office's IFW system, have not been submitted. 69 FR 56481, 56510, Sept. 21, 2004. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information
Disclosure Statement shall not be construed to mean that a search has been made or that no other
material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h),
the filing of this Supplemental Information Disclosure Statement shall not be construed to be an

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The book referenced in the specification for general, conventional scientific techniques, specifically, Gilman et al., "The Pharmacological Basis of Therapeutics," Remington's Pharmaceutical Sciences, 7th Edition, Mack Publishing Co., Easton, PA, 1985, is not relevant to the patentability of the claimed subject matter of the above-referenced application and has not been listed or submitted. If the Examiner requires a copy of this book, one will be furnished upon request.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

This Supplemental Information Disclosure Statement is filed with a Request for Continued Examination pursuant to 37 C.F.R. § 1.114. Thus, Applicants believe no fee is due with this submission. The Director is authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed with this submission (or with any paper filed in this application by this firm) to our Deposit Account No. 50-2228, from which the undersigned is authorized to draw, under Order No. 026038.0376PTUS.

Dated: January 28, 2011

Respectfully submitted,

Therese M. Finan Registration No.: 42,533 PATTON BOGGS LLP

8484 Westpark Drive, 9th Floor McLean, Virginia 22102 (703) 744-8069

(703) 744-8001 (Fax) Attorney for Applicant